Healthcare / Health Information ServicesNasdaqGS
$17.73
+0.62 (+3.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $14.4M · quality 77.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$358M
P/E
N/A
•EV/EBITDA
22.2x
↑ROE
-51.9%
↓Gross Margin
58.4%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
+17.0%
FCF CAGR
+10.7%
FCF margin
18.2%
FCF / Net income
-0.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $79.2M · net income $-64.7M · FCF $14.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $79.2M | $79.2M | $70.0M | $59.6M | $53.9M | $46.5M | $41.6M | $34.0M | $29.7M | $24.1M | $20.0M | $18.3M | $11.5M | $10.1M | $9.4M | $8.7M |
| Net Income | $-64.7M | $-64.7M | $10.0M | $10.0M | $12.5M | $9.8M | $9.3M | $8.6M | $8.9M | $5.8M | $5.0M | $3.8M | $3.0M | $2.9M | $3.0M | $2.7M |
| EBITDA | $14.7M | $14.7M | $11.8M | $13.1M | $18.5M | $14.8M | $14.6M | $13.4M | $13.0M | $10.4M | $9.2M | $7.8M | $4.5M | $4.1M | $3.7M | $3.6M |
| EPS | -3.22 | -3.22 | 0.49 | 0.49 | 0.60 | 0.47 | 0.50 | 0.48 | 0.50 | 0.33 | 0.29 | 0.23 | 0.18 | 0.18 | 0.19 | 0.17 |
| Gross Margin | 58.4% | 58.4% | 61.6% | 80.5% | 79.9% | 77.2% | 74.4% | 73.4% | 73.1% | 73.9% | 77.0% | 76.0% | 85.8% | 83.7% | 84.0% | 82.2% |
| Operating Margin | 8.2% | 8.2% | 8.8% | 15.5% | 27.7% | 24.2% | 27.9% | 31.3% | 34.7% | 34.2% | 36.2% | 32.0% | 38.7% | 40.4% | 38.2% | 40.4% |
| Net Margin | -81.7% | -81.7% | 14.2% | 16.7% | 23.2% | 21.1% | 22.4% | 25.3% | 30.1% | 24.0% | 24.8% | 21.0% | 26.4% | 28.7% | 32.0% | 31.1% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | — | — | — | 0.10 | 0.22 | — | — | — | — | — | — |
| Current Ratio | 5.47 | 5.47 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $14.4M | $14.4M | $9.0M | $17.6M | $13.9M | $17.6M | $10.7M | $11.5M | $9.1M | $6.7M | $5.4M | $7.1M | — | $2.5M | $3.7M | $3.5M |
| Returns | ||||||||||||||||
| ROE | -51.9% | -51.9% | 5.5% | 5.9% | 7.0% | 5.9% | 6.0% | 22.8% | 28.0% | 22.4% | 21.8% | 19.7% | 19.6% | 20.3% | 20.0% | 19.3% |
| Valuation | ||||||||||||||||
| P/E | — | — | 70.41 | 85.31 | 99.77 | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 22.18 | 22.18 | 58.59 | 61.16 | 64.48 | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 2.86 | 2.86 | 3.84 | 5.03 | 6.97 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | 13.1% | 13.1% | 17.5% | 10.5% | — | 11.7% | 22.4% | 14.5% | 22.9% | 20.9% | 9.1% | 59.8% | 13.8% | 6.6% | 8.1% | — |
| EPS Growth | -757.1% | -757.1% | 0.0% | -18.3% | — | -6.0% | 4.2% | -4.0% | 51.5% | 13.8% | 26.1% | 27.8% | 0.0% | -5.3% | 11.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-44.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.49 → -3.22
Residual
-44.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.